By Fineline Cube 
Guangzhou-based electrophysiology platform company EnChannel Medical Ltd. is set to acquire the AcQMap High Resolution Imaging and Mapping platform assets from US-based Acutus Medical Inc. (OTC: AFIB). The transaction includes critical intellectual property (IP) portfolio, quality/regulatory documentation, clinical datasets, select AcQMap hardware, and related catheter R&D assets.
AcQMap Technology Highlights
AcQMap is a second-generation non-contact mapping system that features charge-density mapping, representing a significant advancement from conventional voltage-voltage mapping. Equipped with a multi-electrode array in the heart cavity to collect electrical signals within a single heartbeat cycle, this platform can reconstruct real-time three-dimensional excitation images of the entire atrium. This capability significantly improves mapping efficiency and tracking ability for complex arrhythmias such as atrial fibrillation.
Strategic Benefits for EnChannel
The transaction is expected to strengthen EnChannel’s IP portfolio for Gen2/Gen3 non-contact mapping technology. The company’s in-house developed third-generation “Action Potential Mapping” is the first to achieve precise tracking of cardiac depolarization and repolarization processes. This advancement provides a more comprehensive electrophysiological map basis for persistent atrial fibrillation, positioning EnChannel at the forefront of innovative electrophysiology solutions.-Fineline Info & Tech